MC

MedCap AB (publ)STO MedCap AB Stock Report

Last reporting period 30 Jun, 2024

Updated 29 Oct, 2024

Last price

Market cap $B

0.708

Micro

Exchange

XSTO - Nasdaq STOCKHOLM AB

MCAP.ST Stock Analysis

MC

Neutral

Based on Eyestock quantitative analysis, MCAP.ST`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

100/100

High score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-14.0 %

Overvalued

Market cap $B

0.708

Dividend yield

Shares outstanding

14.807 B

MedCap AB is an investment company engaged in biotechnology and medical technology capital investments. The company is headquartered in Solna, Stockholm. The company went IPO on 2006-07-04. The firm reports four segments: Abilia, Unimedic, Quickels and Inpac. The Company’s portfolio includes such companies as Abilia AB, which is engaged in the development and marketing of aids within the fields of communication, cognition, noise and environmental control; Unimedic AB, engaged in contract manufacturing of liquid pharmaceuticals; Quickels Systems AB, which is engaged in the development and marketing of intensive medical care equipment, such as care bags and electrocardiogram (ECG) equipment; AirContainer Package System AB that offers a wide range of packaging solutions for the pharmaceutical industry, and Dunmedic AB, which offers medical products, medicines and food supplements.

View Section: Eyestock Rating